News | November 28, 2023
Fortis Healthcare to divest Fortis Malar Hospital, Chennai to MGM Healthcare
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Total transaction value of the divestment is Rs. 3,660 million
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
The introduction of 'Definisse Core Filler' is a testament to the company's premium scientific-based innovation
Lupin has been exclusively marketing these brands in the Indian market since July 2021
Ronco succeeds Dr. Christine Dingivan, who will now serve as a senior advisor to Executive Chairman Sastry Chilukuri
AHH will make an investment of Rs. 600 crore in the company through a mix of primary and secondary infusion
This advanced technology is specifically tailored for individuals with high power prescriptions, aiming to free the 18-35 age group from the reliance on eyeglasses
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
